Status:
COMPLETED
Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
Lead Sponsor:
University of Missouri-Columbia
Conditions:
SARS-CoV 2
ARDS
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is designed to evaluate a potential mechanism by which a hyperactive immune response may contribute to death from SARS-CoV-2; by an excessive neutrophil-mediated deposition of cell-free DNA...
Detailed Description
Severe cases of SARS-CoV-2 infection have shown an inflammatory neutrophil and mucus-mediated airway exclusion pathway similar to previously described acute respiratory distress syndrome (ARDS) in oth...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Hospitalized and mechanically ventilated for illness related to SARS-CoV-2
- Confirmed positive SARS-CoV-2 infection by Polymerase chain reaction (PCR)
- individual or surrogate ability to sign informed consent
- negative, urine-based pregnancy test in females
Exclusion
- contraindication or intolerance to dornase alfa
- mechanical ventilation expected to be less than 48 hours
- life expectancy less than 24 hours based upon judgement of treating physician
- pregnant
- inability to obtain informed consent
Key Trial Info
Start Date :
June 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04402970
Start Date
June 19 2020
End Date
December 31 2020
Last Update
April 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Missouri Hospital and Clinics
Columbia, Missouri, United States, 65212